154361-50-9 | Capecitabine

Chemical type

• Oral fluoropyrimidine prodrug

^[1]

• Fluoropyrimidine pro-drug

^[2]

Key properties

• Converts to 5-FU (5-fluorouracil) via thymidine phosphorylase
• Induces apoptosis through caspase activation
• Down-regulates NF-κB
• Upregulates caspase-3 and caspase-9
• May down-regulate p53 in single treatment

^[1]

• An orally administered chemotherapeutic agent that is metabolized to 5-fluorouracil (5-FU) in the body

^[2]

• Chemotherapeutic agent for colorectal cancer
• Part of regimens like FOLFOX or as monotherapy
• Combination with irinotecan and 17-AAG for enhanced apoptosis
• Treatment of HT-29 colon cancer cells

^[1]

• First-line treatment for metastatic colorectal cancer (mCRC); used in combination therapy with PD-1 inhibitors

^[2]

Classification by use

• Chemicals used in cancer chemotherapy
• Chemicals used as prodrugs
• Chemicals used as apoptosis inducers

^[1]

• Chemotherapy agent

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29), Annals of Medicine and Surgery, Volume 78, June 2022, 103850
2. [Cite:2] Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors, Iscience, Volume 28, Issue 12, 19 December 2025, 114202